<DOC>
	<DOCNO>NCT02071342</DOCNO>
	<brief_summary>The aim study evaluate clinical outcome 30 day 1 year ( cardiac death , myocardial infarction , target lesion revascularization ( TLR ) , target vessel revascularization ( TVR ) , thrombosis device patient undergo angioplasty myocardial infarction bioabsorbable stent implant ( BVS ) . Additionally , evaluate acute recoil implantation bioabsorbable stent . A 24 month follow-up , mean coronary angiography accompany QCA assessment intracoronary ultrasound ( IVUS ) VH ( virtual histology ) schedule .</brief_summary>
	<brief_title>Study ABSORB Stent Acute Myocardial Infarction</brief_title>
	<detailed_description>The drug -eluting stent ( drug elute stent , DES ) currently use routinely course coronary angioplasty ( percutaneous coronary intervention , PCI ) significantly reduce incidence adverse event follow-up medium long term . However , persistence metal structure device within coronary artery time add additional benefit , contrary , potentially harmful may predispose coronary thrombosis even year implantation , alter structure vessel remodel phenomenon , decrease coronary vasomotion reduce possibilily future surgery . The recent development new device bioabsorbable vascular scaffold `` BVS `` release antiproliferative drug ( everolimus ) , could provide new clinical advantage especially patient revascularized acute myocardial infarction . These patient high risk MACE stent thrombosis late . The aim study evaluate clinical outcome conventional 30 day 1 year , cardiac death , myocardial infarction , target lesion revascularization ( TLR ) , target vessel revascularization ( TVR ) , thrombosis device patient undergo angioplasty course acute coronary syndrome implant bioabsorbable stent ( BVS ) . The acute recoil implantation bioresorbable vascular scaffold also assess Finally , follow-up 24 month conduct , mean coronary angiography accompany QCA IVUS VH .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>patient older 18 year acute coronary syndrome ( STEMI NSTEMI ) enrol patient characteristic exclude : cardiogenic shock ( define systolic blood pressure le 80 mmHg 30 minute need compressor intravenousintraaortic balloon counterpulsation ) , history bleeding diathesis , history leukopenia , thrombocytopenia , severe hepatic renal dysfunction , noncardiac disease associate life expectancy le one year , participate another study , able give inform consent due prolong resuscitation cardiopulmonary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>acute myocardial infarction</keyword>
	<keyword>bioresorbable vascular scaffold</keyword>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>